News
BBNX
11.05
-2.90%
-0.33
Beta Bionics Insiders Quietly Cash Out in a Wave of Executive Stock Sales
TipRanks · 2d ago
Faruqi & Faruqi Probes Beta Bionics for Potential Securities Claims
Reuters · 2d ago
Weekly Report: what happened at BBNX last week (0223-0227)?
Weekly Report · 3d ago
Lowest Quant ranked small-cap stocks with positive EPS surprises
Seeking Alpha · 02/25 20:41
Beta Bionics Discloses FDA Warning Letter Over iLet Quality System Issues
Reuters · 02/25 17:54
Faruqi & Faruqi Probes Beta Bionics for Potential Investor Claims
Reuters · 02/24 22:41
Beta Bionics files automatic mixed securities shelf
TipRanks · 02/24 22:20
Beta Bionics Files For Mixed Shelf; Size Not Disclosed
Benzinga · 02/24 22:06
BETA BIONICS INC FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING
Reuters · 02/24 22:04
Weekly Report: what happened at BBNX last week (0216-0220)?
Weekly Report · 02/23 09:34
Beta Bionics to Present at TD Cowen 46th Annual Health Care Conference
Reuters · 02/19 21:05
Faruqi & Faruqi Probes Investor Claims Against Beta Bionics Inc
Reuters · 02/19 14:21
Beta Bionics Price Target Cut to $22.00/Share From $25.00 by Stifel
Dow Jones · 02/18 14:39
Beta Bionics Is Maintained at Buy by Stifel
Dow Jones · 02/18 14:39
Stifel Maintains Buy on Beta Bionics, Lowers Price Target to $22
Benzinga · 02/18 14:29
Expert Outlook: Beta Bionics Through The Eyes Of 7 Analysts
Benzinga · 02/18 14:00
Beta Bionics price target lowered to $20 from $40 at Lake Street
TipRanks · 02/18 13:45
Beta Bionics Is Maintained at Neutral by Baird
Dow Jones · 02/18 13:14
Beta Bionics Price Target Cut to $14.00/Share From $28.00 by Baird
Dow Jones · 02/18 13:14
Baird Maintains Neutral on Beta Bionics, Lowers Price Target to $14
Benzinga · 02/18 13:03
More
Webull provides a variety of real-time BBNX stock news. You can receive the latest news about Beta Bionics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BBNX
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.